Roy joined Advent in 2015 and brings over 25 years of drug discovery, drug development and entrepreneurial experience
Roy obtained a D.Phil. from Oxford University for work on zinc metalloenzymes before becoming Assistant Professor of Pathology at Harvard Medical School. Roy then spent 15 years at Biogen Inc, where he discovered the pathway that enabled the development of the drug TysabriTM, used to treat severe multiple sclerosis. At Biogen, Roy was Senior Director, Exploratory Research and was responsible for overseeing all immunology and inflammation-directed research.
Since leaving Biogen, Roy has cofounded multiple Biotechnology Companies, including: Albor Biologics, set up to commercialize IP around the function of the leukocyte activation molecule CD69 from the University of Madrid; Avila Therapeutics, set up to develop covalent small molecule drugs using structure-based drug design; and Alvos Therapeutics, set up to develop novel cell surface tumor proteins identified at M D Anderson Cancer Center by Drs. Pasqualini and Arap through in vivo phage display.
Roy is a Founder and Director of the portfolio Company Aleta Biotherapeutics, as well as an advisor to other Advent portfolio Companies.